Endoscopic surveillance in Barrett's esophagus

Area of Science:

• Gastroenterology
• Oncology
• Gastroesophageal Reflux Disease (GERD)

Background:

• Barrett's esophagus (BE) is a premalignant condition for esophageal adenocarcinoma, a cancer with rapidly increasing incidence.
• Chronic gastroesophageal reflux disease (GORD) is a known risk factor for developing BE.
• Current recommendations for BE involve regular endoscopic surveillance due to its premalignant nature.

Purpose of the Study:

• To critically evaluate the assumptions underlying the recommendation for endoscopic surveillance in Barrett's esophagus.
• To discuss the limitations and controversies surrounding the efficacy of endoscopic surveillance for detecting early neoplasia in BE.
• To review current American College of Gastroenterology guidelines for managing BE based on dysplasia grade.

Main Methods:

• Review of existing literature and guidelines regarding Barrett's esophagus surveillance.
• Analysis of the controversial assumptions supporting surveillance: survival impact and early detection reliability.
• Examination of reported cancer incidence rates in prospective studies of BE patients.

Main Results:

• The efficacy of endoscopic surveillance for BE is debated, with controversial assumptions regarding survival benefits and reliable early neoplasia detection.
• Low reported cancer incidence rates (0.5%-1.9%) in prospective BE studies are cited to question the necessity of surveillance.
• Current guidelines recommend surveillance intervals based on dysplasia grade, ranging from 6 months to 3 years, with options for resection in high-grade dysplasia.

Conclusions:

• The effectiveness of endoscopic surveillance in Barrett's esophagus remains uncertain due to a lack of understanding of dysplasia's natural history and controversial supporting data.
• Future advancements in dysplasia detection (biochemical markers, advanced imaging) and treatment (ablative techniques) may refine surveillance protocols.
• Currently, no definitive marker other than dysplasia has been established to identify high-risk individuals for targeted endoscopic surveillance in BE.